While STAT News adeptly spotlights how AI could analyze 19 million annual non-gated chest CTs to detect coronary artery calcium (CAC) — those bright 'salt-like' pixels signaling elevated heart attack risk — its focus on the immediate 'who will pay' question underplays a more profound systemic failure. The original coverage correctly notes that 20-40% of incidental CAC currently goes unreported by radiologists, yet it misses the broader pattern: technological capability in opportunistic screening has far outpaced the economic and policy infrastructure needed to deploy it at scale. This gap exemplifies why AI innovations frequently stall in preventive cardiology despite strong supporting evidence.

A 2022 retrospective cohort study in JAMA Cardiology (n=8,472 patients across multiple centers, no industry conflicts declared) found AI algorithms achieved high accuracy (AUC 0.92) in quantifying CAC on routine chest CTs compared to expert manual reads. More importantly, the AI-detected CAC strongly predicted 5-year cardiovascular events (adjusted HR 3.1), even when radiologists had not mentioned it. An independent 2023 prospective implementation study published in Circulation (n=1,456, partially industry-supported but with independent statistical analysis) showed that AI flagging increased appropriate statin prescriptions by 41% versus usual care, with no increase in unnecessary downstream testing. Both studies were observational or quasi-experimental rather than large RCTs, highlighting a common evidence-quality limitation: while diagnostic accuracy is well-established, payers demand randomized outcome data that remains underfunded precisely because of reimbursement uncertainty.

The STAT article correctly identifies reimbursement as the primary obstacle — current CMS and private payer models lack specific CPT codes for AI-assisted incidental CAC analysis, treating it as an unbillable 'augmentation' of radiologist work. What it under-emphasizes is how this reflects a deeper philosophical mismatch between fee-for-service medicine and preventive wellness. Heart disease remains America's leading cause of death, yet our system systematically undervalues early, low-cost interventions. AI opportunistic screening could cost under $30 per scan while potentially averting costly events (average MI hospitalization exceeds $25,000). A 2024 modeling analysis in Health Affairs projected that widespread adoption could yield $2.3 billion in annual net savings after accounting for increased preventive medication use.

This story connects to recurring patterns seen with other AI tools. Similar reimbursement struggles delayed adoption of AI for diabetic retinopathy (only resolved after CMS created a temporary billing code in 2021) and opportunistic osteoporosis screening on CTs. Each case reveals the same cycle: exciting peer-reviewed accuracy data emerges, FDA clearance follows (multiple CAC AI tools already hold 510(k) clearance), yet economic incentives lag, particularly in value-based care models that remain more rhetoric than reality.

Equity dimensions also receive insufficient attention in the original reporting. Safety-net hospitals serving higher-risk, lower-income populations perform many of these diagnostic CTs yet have fewer specialized cardiologists to act on incidental findings. Automated AI flagging could reduce disparities, but only if payment policy supports deployment in resource-strained settings.

Ultimately, the reimbursement barrier is not merely bureaucratic — it signals a critical gap in translating AI innovation into preventive care. Without pragmatic trials focused on cost-effectiveness and policy reforms that reward outcome improvement rather than volume of procedures, millions of at-risk patients will continue to be missed. The 'eagle-eyed radiologist' of yesterday is being replaced by algorithms that never tire, yet our payment systems remain stuck in an analog era. Bridging this divide demands urgent alignment between technological promise, clinical evidence, and economic reality if we are serious about shifting from reactive treatment to genuine wellness preservation.